{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:21:56Z","timestamp":1740162116243,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["Z01 CP010136"],"award-info":[{"award-number":["Z01 CP010136"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30 AR079369"],"award-info":[{"award-number":["P30 AR079369"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Impact<\/jats:title><jats:p><jats:list list-type=\"bullet\">\n                <jats:list-item>\n                  <jats:p>Immune dysregulation is thought to contribute to chronic lymphocytic leukemia (CLL) risk, but biological mechanisms are unclear. We discovered that increased serum levels of B-cell activating factor (BAFF), an important regulator of B-cell maturation, were associated with a decreased risk of CLL, even &gt;10\u2009years after blood draw. Our findings suggest that BAFF could be a useful biomarker to assess risk among individuals at high risk, such as those with monoclonal b-cell lymphocytosis.<\/jats:p>\n                <\/jats:list-item>\n              <\/jats:list><\/jats:p>","DOI":"10.1038\/s41408-024-01106-7","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T13:05:38Z","timestamp":1723035938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum levels of B-cell activating factor are associated with a reduced risk of chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1558-4945","authenticated-orcid":false,"given":"Eleanor","family":"Frost","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1043-5812","authenticated-orcid":false,"given":"Jonathan N.","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4440-3368","authenticated-orcid":false,"given":"Wen-Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley A.","family":"Frazer-Abel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin D.","family":"Deane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5230-0652","authenticated-orcid":false,"given":"Sonja I.","family":"Berndt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"1106_CR1","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","volume":"165","author":"E Zintzaras","year":"2005","unstructured":"Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165:2337\u201344. https:\/\/doi.org\/10.1001\/archinte.165.20.2337","journal-title":"Arch Intern Med"},{"key":"1106_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/jncimonographs\/lgu013","volume":"2014","author":"LM Morton","year":"2014","unstructured":"Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, et al. Etiologic heterogeneity among non-hodgkin lymphoma subtypes: the InterLymph non-hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014:130\u201344. https:\/\/doi.org\/10.1093\/jncimonographs\/lgu013","journal-title":"J Natl Cancer Inst Monogr"},{"key":"1106_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/cancers12020282","volume":"12","author":"C Vitale","year":"2020","unstructured":"Vitale C, Montalbano MC, Salvetti C, Boccellato E, Griggio V, Boccadoro M, et al. Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs. Cancers (Basel). 2020;12:282 https:\/\/doi.org\/10.3390\/cancers12020282","journal-title":"Cancers (Basel)"},{"key":"1106_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/jncimonographs\/lgu001","volume":"2014","author":"SL Slager","year":"2014","unstructured":"Slager SL, Benavente Y, Blair A, Vermeulen R, Cerhan JR, Seniori, et al. Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia\/small lymphocytic lymphoma: the InterLymph non-hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014:41\u201351. https:\/\/doi.org\/10.1093\/jncimonographs\/lgu001","journal-title":"J Natl Cancer Inst Monogr"},{"key":"1106_CR5","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/annonc\/mdv231","volume":"26","author":"J Helby","year":"2015","unstructured":"Helby J, Bojesen SE, Nielsen SF, Nordestgaard BG. IgE and risk of cancer in 37 747 individuals from the general population. Ann Oncol. 2015;26:1784\u201390. https:\/\/doi.org\/10.1093\/annonc\/mdv231","journal-title":"Ann Oncol"},{"key":"1106_CR6","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1093\/carcin\/bgu188","volume":"35","author":"A Nieters","year":"2014","unstructured":"Nieters A, \u0141uczy\u0144ska A, Becker S, Becker N, Vermeulen R, Overvad K, et al. Prediagnostic immunoglobulin E levels and risk of chronic lymphocytic leukemia, other lymphomas and multiple myeloma-results of the European prospective investigation into cancer and nutrition. Carcinogenesis. 2014;35:2716\u201322. https:\/\/doi.org\/10.1093\/carcin\/bgu188","journal-title":"Carcinogenesis"},{"key":"1106_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/039463200702000101","volume":"20","author":"S Bosello","year":"2007","unstructured":"Bosello S, Pers JO, Rochas C, Devauchelle V, De Santis M, Daridon C, et al. BAFF and rheumatic autoimmune disorders: implications for disease management and therapy. Int J Immunopathol Pharm. 2007;20:1\u20138.","journal-title":"Int J Immunopathol Pharm"},{"key":"1106_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaci.2008.11.022","volume":"123","author":"A Kato","year":"2009","unstructured":"Kato A, Xiao H, Chustz RT, Liu MC, Schleimer RP. Local release of B cell-activating factor of the TNF family after segmental allergen challenge of allergic subjects. J Allergy Clin Immunol. 2009;123:369\u201375. https:\/\/doi.org\/10.1016\/j.jaci.2008.11.022","journal-title":"J Allergy Clin Immunol"},{"key":"1106_CR9","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1016\/j.ijporl.2014.09.031","volume":"78","author":"W Liu","year":"2014","unstructured":"Liu W, Sun C, Luo X, Han M, Zhou L, Li J, et al. Elevated B cell-activating factor (BAFF) in children with allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2014;78:2156\u201360. https:\/\/doi.org\/10.1016\/j.ijporl.2014.09.031","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"1106_CR10","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.3390\/cancers15215231","volume":"15","author":"E Frost","year":"2023","unstructured":"Frost E, Hofmann JN, Huang WY, Parks CG, Frazer-Abel AA, Deane KD, et al. Antinuclear antibodies are associated with an increased risk of diffuse large B-cell lymphoma. Cancers (Basel). 2023;15:5231. https:\/\/doi.org\/10.3390\/cancers15215231","journal-title":"Cancers (Basel)"},{"key":"1106_CR11","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.3324\/haematol.2017.183236","volume":"103","author":"MM Epstein","year":"2018","unstructured":"Epstein MM, Rosner B, Breen EC, Batista JL, Giovannucci EL, Magpantay L, et al. Pre-diagnosis plasma immune markers and risk of non-hodgkin lymphoma in two prospective cohort studies. Haematologica. 2018;103:1679\u201387. https:\/\/doi.org\/10.3324\/haematol.2017.183236","journal-title":"Haematologica"},{"key":"1106_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1600-0609.2010.01482.x","volume":"85","author":"S Molica","year":"2010","unstructured":"Molica S, Digiesi G, Battaglia C, Cutrona G, Antenucci A, Molica M, et al. Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. Eur J Haematol. 2010;85:314\u201320. https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01482.x","journal-title":"Eur J Haematol"},{"key":"1106_CR13","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.leukres.2009.03.030","volume":"33","author":"A Bojarska-Junak","year":"2009","unstructured":"Bojarska-Junak A, Hus I, Chocholska S, Wasik-Szczepanek E, Sieklucka M, Dmoszy\u00f1ska A, et al. BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. Leuk Res. 2009;33:1319\u201327. https:\/\/doi.org\/10.1016\/j.leukres.2009.03.030","journal-title":"Leuk Res"},{"key":"1106_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s12288-018-1029-7","volume":"35","author":"I Berke Mentese","year":"2019","unstructured":"Berke Mentese I, Yegin ZA, Gokcen S, Ozkurt ZN, Yagci M. Prognostic significance of serum BAFF, APRIL, TACI and BCMA levels in chronic lymphocytic leukemia. Indian J Hematol Blood Transfus. 2019;35:265\u201371. https:\/\/doi.org\/10.1007\/s12288-018-1029-7","journal-title":"Indian J Hematol Blood Transfus"},{"key":"1106_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/478753","volume":"2015","author":"A Mamara","year":"2015","unstructured":"Mamara A, Germenis AE, Kompoti M, Palassopoulou M, Mandala E, Banti A, et al. TACI expression and signaling in chronic lymphocytic leukemia. J Immunol Res. 2015;2015:478753 https:\/\/doi.org\/10.1155\/2015\/478753","journal-title":"J Immunol Res"},{"key":"1106_CR16","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.3109\/10428194.2011.591008","volume":"52","author":"G Ferrer","year":"2011","unstructured":"Ferrer G, Hodgson K, Pereira A, Juan M, Elena M, Colomer D, et al. Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2011;52:2064\u20138. https:\/\/doi.org\/10.3109\/10428194.2011.591008","journal-title":"Leuk Lymphoma"},{"key":"1106_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1182\/blood-2006-06-027755","volume":"109","author":"T Endo","year":"2007","unstructured":"Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood. 2007;109:703\u201310. https:\/\/doi.org\/10.1182\/blood-2006-06-027755","journal-title":"Blood"},{"key":"1106_CR18","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/1521-4141(200207)32:7<2004::AID-IMMU2004>3.0.CO;2-5","volume":"32","author":"AG Rolink","year":"2002","unstructured":"Rolink AG, Tschopp J, Schneider P, Melchers F. BAFF is a survival and maturation factor for mouse B cells. Eur J Immunol. 2002;32:2004\u201310. https:\/\/doi.org\/10.1002\/1521-4141(200207)32:7<2004::AID-IMMU2004>3.0.CO;2-5","journal-title":"Eur J Immunol"},{"key":"1106_CR19","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1126\/science.1061964","volume":"293","author":"B Schiemann","year":"2001","unstructured":"Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001;293:2111\u20134. https:\/\/doi.org\/10.1126\/science.1061964","journal-title":"Science"},{"key":"1106_CR20","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jaci.2015.03.022","volume":"136","author":"AC Lundell","year":"2015","unstructured":"Lundell AC, Hesselmar B, Nordstr\u00f6m I, Adlerberth I, Wold AE, Rudin A. Higher B-cell activating factor levels at birth are positively associated with maternal dairy farm exposure and negatively related to allergy development. J Allergy Clin Immunol. 2015;136:1074\u2013.e3. https:\/\/doi.org\/10.1016\/j.jaci.2015.03.022","journal-title":"J Allergy Clin Immunol"},{"key":"1106_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3390\/cells10030647","volume":"10","author":"A Floudas","year":"2021","unstructured":"Floudas A, Canavan M, McGarry T, Mullan R, Nagpal S, Veale DJ, et al. ACPA status correlates with differential immune profile in patients with rheumatoid arthritis. Cells. 2021;10:647 https:\/\/doi.org\/10.3390\/cells10030647","journal-title":"Cells"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01106-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01106-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01106-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T13:07:04Z","timestamp":1723036024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01106-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1106"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01106-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"type":"electronic","value":"2044-5385"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"9 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AAF-A consults for the companies, Ionis Pharmaceuticals and Pfizer. KDD consults for the company Werfen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Boards at the study centers and the National Cancer Institute.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"132"}}